Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hamid Emamekhoo

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2026
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1Mary-Ellen Taplin, Irbaz Bin Riaz, R Bryan Rumble, et al.
Journal for Immunotherapy of Cancer|February 23, 2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023Monika Joshi, Leonard Tuanquin, Junjia Zhu, et al.
Cell Reports. Medicine|May 7, 2026
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A Braun, Marcus S Noel, Ryan H Moy, et al.
JAMA Oncology|August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical TrialSumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO GuidelineW Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
The Journal of Clinical Investigation|June 26, 2018
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancerMohammad Alyamani, Hamid Emamekhoo, Sunho Park, et al.
Targeted Oncology|September 30, 2018
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial CarcinomaAlice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, et al.
Cancer|November 16, 2021
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920Hamid Emamekhoo, Mark R Olsen, Bradley C Carthon, et al.
Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Urologic Oncology|April 3, 2018
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomyMoshe C Ornstein, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2026
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1Mary-Ellen Taplin, Irbaz Bin Riaz, R Bryan Rumble, et al.
Journal for Immunotherapy of Cancer|February 23, 2023
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023Monika Joshi, Leonard Tuanquin, Junjia Zhu, et al.
Cell Reports. Medicine|May 7, 2026
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial resultsDavid A Braun, Marcus S Noel, Ryan H Moy, et al.
JAMA Oncology|August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical TrialSumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2022
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO GuidelineW Kimryn Rathmell, R Bryan Rumble, Peter J Van Veldhuizen, et al.
The Journal of Clinical Investigation|June 26, 2018
HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancerMohammad Alyamani, Hamid Emamekhoo, Sunho Park, et al.
Targeted Oncology|September 30, 2018
Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial CarcinomaAlice Tzeng, C Marcela Diaz-Montero, Patricia A Rayman, et al.
Cancer|November 16, 2021
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920Hamid Emamekhoo, Mark R Olsen, Bradley C Carthon, et al.
Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Urologic Oncology|April 3, 2018
Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomyMoshe C Ornstein, Claudia Marcela Diaz-Montero, Patricia Rayman, et al.
Pageof 7